Jefferies Keeps Their Buy Rating on Humana (HUM)
Jefferies analyst David Windley maintained a Buy rating on Humana today and set a price target of $235.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Windley is a 5-star analyst with an average return of 7.9% and a 56.97% success rate. Windley covers the Healthcare sector, focusing on stocks such as Humana, Charles River Labs, and UnitedHealth.
In addition to Jefferies, Humana also received a Buy from Oppenheimer’s Michael Wiederhorn in a report issued on February 12. However, on February 25, Barclays maintained a Hold rating on Humana (NYSE: HUM).
Based on Humana’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $32.52 billion and a GAAP net loss of $796 million. In comparison, last year the company earned a revenue of $29.21 billion and had a GAAP net loss of $693 million
Read More on HUM:
Disclaimer & DisclosureReport an Issue
- Humana price target lowered to $176 from $245 at Barclays
- Humana: Uncertain Margin Recovery and Star Rating Headwinds Drive Neutral ‘Hold’ Stance
- Humana price target lowered to $206 from $290 at Wells Fargo
- Humana price target lowered to $200 from $285 at Truist
- Humana price target lowered to $173 from $260 at TD Cowen
